ATE386013T1 - Ortho-substituierte benzoesäurederivate zur behandlung von insulinresistenz - Google Patents

Ortho-substituierte benzoesäurederivate zur behandlung von insulinresistenz

Info

Publication number
ATE386013T1
ATE386013T1 AT03732713T AT03732713T ATE386013T1 AT E386013 T1 ATE386013 T1 AT E386013T1 AT 03732713 T AT03732713 T AT 03732713T AT 03732713 T AT03732713 T AT 03732713T AT E386013 T1 ATE386013 T1 AT E386013T1
Authority
AT
Austria
Prior art keywords
ortho
treatment
benzoic acid
acid derivatives
insulin resistance
Prior art date
Application number
AT03732713T
Other languages
English (en)
Inventor
Lanna Li
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0201935A external-priority patent/SE0201935D0/xx
Priority claimed from SE0203826A external-priority patent/SE0203826D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE386013T1 publication Critical patent/ATE386013T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT03732713T 2002-06-20 2003-06-17 Ortho-substituierte benzoesäurederivate zur behandlung von insulinresistenz ATE386013T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0201935A SE0201935D0 (sv) 2002-06-20 2002-06-20 Therapeutic agents
SE0203826A SE0203826D0 (sv) 2002-12-20 2002-12-20 Therapeutic agents

Publications (1)

Publication Number Publication Date
ATE386013T1 true ATE386013T1 (de) 2008-03-15

Family

ID=30002442

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03732713T ATE386013T1 (de) 2002-06-20 2003-06-17 Ortho-substituierte benzoesäurederivate zur behandlung von insulinresistenz

Country Status (22)

Country Link
US (1) US7355069B2 (de)
EP (1) EP1517883B8 (de)
JP (2) JP3782818B2 (de)
KR (1) KR20050014013A (de)
CN (1) CN1319938C (de)
AR (1) AR039713A1 (de)
AT (1) ATE386013T1 (de)
AU (1) AU2003240099B2 (de)
BR (1) BR0311932A (de)
CA (1) CA2489834C (de)
DE (1) DE60319084T2 (de)
DK (1) DK1517883T3 (de)
ES (1) ES2299702T3 (de)
IL (1) IL165671A0 (de)
IS (1) IS7627A (de)
MX (1) MXPA04012686A (de)
NO (1) NO20045353L (de)
PL (1) PL375074A1 (de)
PT (1) PT1517883E (de)
RU (1) RU2004137094A (de)
TW (1) TWI282784B (de)
WO (1) WO2004000790A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576131B2 (en) * 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
SE0104333D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
FR2875805B1 (fr) * 2004-09-27 2006-12-29 Genfit S A Composes derives de n-(benzyl) phenylacetamide substitues, preparation et utilisations
GB0522431D0 (en) * 2005-11-03 2005-12-14 Astrazeneca Ab Chemical process
GB0522433D0 (en) * 2005-11-03 2005-12-14 Astrazeneca Ab Therapeutic agents

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK148576A (da) 1975-04-18 1976-10-19 Boehringer Mannheim Gmbh Fenylalkankarbonsyrederivater og fremgangsmade til deres fremstilling
DE19615263A1 (de) * 1996-04-18 1997-10-23 Bayer Ag Benzyloxy-substituierte Phenylglycinolamide
AU9696198A (en) 1997-10-17 1999-05-10 Aventis Pharmaceuticals Products Inc. Therapeutic uses of quinoline derivatives
ATE260103T1 (de) 1997-12-19 2004-03-15 Schering Ag Ortho-anthranilamide derivate als antikoagulantien
SE9801992D0 (sv) 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
GB9822473D0 (en) 1998-10-16 1998-12-09 Glaxo Group Ltd Chemical compounds
PL351470A1 (en) 1999-04-28 2003-04-22 Aventis Pharma Gmbh Tri-aryl acid derivatives as ppar receptor ligands
YU72201A (sh) 1999-04-28 2005-07-19 Aventis Pharma Deutschland Gmbh. Derivati di-aril kiseline kao ppar receptorski ligandi
JP4618845B2 (ja) 1999-06-09 2011-01-26 杏林製薬株式会社 ヒトペルオキシゾーム増殖薬活性化受容体（ＰＰＡＲ）αアゴニストとしての置換フェニルプロピオン酸誘導体
GB9919411D0 (en) 1999-08-18 1999-10-20 Zeneca Ltd Chemical compounds
SE0000772D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab Chemical compounds
US6509374B2 (en) 2000-04-17 2003-01-21 Novo Nordisk A/S Compounds, their preparation and use
SE0003766D0 (sv) 2000-10-18 2000-10-18 Astrazeneca Ab Novel formulation
EG26979A (en) 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
GB0116955D0 (en) 2001-07-11 2001-09-05 Syngenta Ltd Weed control process
GB0121337D0 (en) 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
AU2002329387B2 (en) 2001-09-08 2007-06-07 Albireo Ab Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (IBAT) inhibitory activity for the treatment hyperlipidaemia
SE0104333D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
SE0104334D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
GB0229931D0 (en) 2002-12-21 2003-01-29 Astrazeneca Ab Therapeutic agents
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
SE0201936D0 (sv) 2002-06-20 2002-06-20 Astrazeneca Ab Therapeutic agents
SE0201937D0 (sv) 2002-06-20 2002-06-20 Astrazeneca Ab Therapeutic agents
US7351858B2 (en) 2002-06-20 2008-04-01 Astrazeneca Ab Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
GB0314136D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314131D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314130D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314075D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314078D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314129D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314260D0 (en) 2003-06-19 2003-07-23 Astrazeneca Ab Therapeutic agents

Also Published As

Publication number Publication date
BR0311932A (pt) 2005-03-22
WO2004000790A1 (en) 2003-12-31
IS7627A (is) 2005-01-05
TW200409747A (en) 2004-06-16
KR20050014013A (ko) 2005-02-05
JP3782818B2 (ja) 2006-06-07
MXPA04012686A (es) 2005-03-23
HK1073838A1 (en) 2005-10-21
PT1517883E (pt) 2008-04-21
IL165671A0 (en) 2006-01-15
CN1675171A (zh) 2005-09-28
EP1517883B1 (de) 2008-02-13
DE60319084T2 (de) 2009-01-29
JP2005529970A (ja) 2005-10-06
US20050256198A1 (en) 2005-11-17
EP1517883B8 (de) 2008-05-21
CA2489834A1 (en) 2003-12-31
NO20045353L (no) 2005-01-20
JP2006182782A (ja) 2006-07-13
AR039713A1 (es) 2005-03-09
DK1517883T3 (da) 2008-05-26
RU2004137094A (ru) 2005-08-10
AU2003240099B2 (en) 2007-02-01
ES2299702T3 (es) 2008-06-01
AU2003240099A1 (en) 2004-01-06
CN1319938C (zh) 2007-06-06
CA2489834C (en) 2006-10-03
TWI282784B (en) 2007-06-21
EP1517883A1 (de) 2005-03-30
US7355069B2 (en) 2008-04-08
PL375074A1 (en) 2005-11-14
DE60319084D1 (de) 2008-03-27

Similar Documents

Publication Publication Date Title
ATE524173T1 (de) Verwendung von (-)(3-trihalomethylphenoxy)(4- halophenyl)essigsäurederivaten zur behandlung von hyperurikämie
DE602004028763D1 (de) Te zur behandlung von virenerkrankungen
DE60320007D1 (de) Phenethanolamin-derivate zur behandlung von atemwegserkrankungen
DE602005005810D1 (de) Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
ATE518841T1 (de) Herstellung und verwendung von arylalkylsäurederivaten zur behandlung von obesitas
DE60303238D1 (de) Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
ATE344253T1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
ATE410430T1 (de) 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
DE602005026984D1 (de) Chinolin-derivate zur behandlung von latenter tuberkulose
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
ATE273304T1 (de) (s)-4-amino-5-chloro-2-methoxy-n-(1-(1-(2- tetrahydrofuryl-carbonyl)-4-piperidinylmethyl)- - piperidinyl)benzamid zur behandlung von magen- darmbewegungskrankheiten
ATE476414T1 (de) Biphenyloxyessigsäurederivate zur behandlung von atemwegserkrankungen
ATE517085T1 (de) Zur behandlung von atemwegserkrankungen geeignete phenoxyessigsäurederivate
ATE438623T1 (de) Aroyl-o-piperidinderivate zur behandlung von problemen im zusammenhang mit diabetes
NO20045554L (no) Fremgangsmate for behandling av diabetes
DE602004022035D1 (de) Verwendung von pthalide derivativen zur behandlung
EP1651237A4 (de) Verfahren zur behandlung von dermatologischen erkrankungen
DE60319084D1 (de) Ortho-substituierte benzoesäurederivate zur behandlung von insulinresistenz
ATE330596T1 (de) Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen
DE60319082D1 (de) Ortho-substituierte benzoesäurederivate zur behandlung von insulinresistenz
DE602004007546D1 (de) Verwendung von pentadiensäure-derivaten zur behandlung von hyperurikämie
ATE359270T1 (de) Phenyl-piperidin-4-yliden-methyl-benzamidderiva e zur behandlung von schmerz oder magen-darm- erkrankungen
DE602004015272D1 (de) Verwendung von phenoxyessigsäurederivaten zur behandlung der hyperaktiven blase
DE502004002479D1 (de) Verwendung von acylcyclohexandion-derivaten zusammen mit ethephon zur behandlung von kernobst
DE602004003252D1 (de) Verwendung von 2h-ä1,3ü-oxazinoä3,2-aüindol-derivaten zur behandlung von neuropathischem schmerz

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1517883

Country of ref document: EP

REN Ceased due to non-payment of the annual fee